Eli Lilly's experimental three-hormone combination drug posts 54 pounds of average weight loss in a mid-stage trial, nearly 20 pounds more than its own top-selling tirzepatide alone, with phase 3 trials starting by year end.
Eli Lilly's experimental three-hormone combination drug posts 54 pounds of average weight loss in a mid-stage trial, nearly 20 pounds more than its own top-selling tirzepatide alone, with phase 3 trials starting by year end.